Company intelligence / Profile preview
Structure Therapeutics
South San Francisco, California, United Statesstructuretx.com ↗
- Ownership
- Public · GPCR
- Employees
- ~163
- Development stage
- Other
01
Overview
Structure Therapeutics has advanced multiple oral small molecule programs into clinical development. Its lead candidate GSBR‑1290 targets GLP‑1R for T2DM and obesity. Other programs include dual GLP‑1R/GIPR agonists and amylin agonists for metabolic diseases, as well as ANPA‑0073 and LTSE‑2578 for fibrotic lung diseases. The company’s approach aims to deliver biologic-like efficacy with the convenience of oral dosing[3][1].
- Therapeutic areas
- EndocrinologyPulmonology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Financials
- Market cap
- $1.1B
- Total revenue
- $0
- Enterprise value
- $-238.1M
Beyond the preview
Go deeper on Structure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Structure Therapeutics.